Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo

Cancer Research

Volumn 59, Issue 7, 1999, Pages 1485-1491

  Westphal, Eva Maria ^a   Mauser, Amy ^a   Swenson, Jennifer ^a   Davis, Michelle G ^c   Talarico, Christine L ^c   Kenney, Shannon C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; ARTICLE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; VIRUS ACTIVATION; VIRUS CARCINOGENESIS; VIRUS GENOME; VIRUS INFECTION;

ADENOVIRIDAE; ANIMALS; BURKITT LYMPHOMA; DNA-BINDING PROTEINS; GANCICLOVIR; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; MICE; MICE, SCID; PHOSPHORYLATION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VIRAL PROTEINS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0033118418     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Rickinson, A., and Kieff, E. Epstein-Barr virus. In: B. Fields, D. Knipe, and P. Howley (eds.), Field's Virology, Ed. 3, pp. 2397-2415. Philadelphia: Lippincott-Raven Publishers, 1996.
2. Harabuchi, Y., Yamanaka, N., Kataura, A., Kinoshita, T., Mizuno, F., and Osato, T. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal mid-line granuloma. Lancet, i: 128-130, 1990.
3. Lee, E., Locker, J., Nalesnik, M., Reyes, J., Jaffe, R., Alashari, M., Nour, B., Tzakis, A., and Dickman, P. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N. Engl. J. Med., 332: 19-25, 1995.
4. McClain, K., Leach, C., Jenson, H., Joshi, V., Pollock, B., Parmley, R., DiCarlo, F., Chadwick, F., and Murphy, S. Association of Epstein-Barr virus with leiomyosarcoma in children with AIDS. N. Engl. J. Med., 332: 12-18, 1995.
5. Shibata, D., and Weiss, L. Epstein-Barr virus associated gastric carcinoma. Am. J. Pathol., 140: 769-774, 1992.
6. MacMahon, E. M. E., Glass, J. D., Hayward, S. D., Mann, R. B., Becker, P. S., Charache, P., McArthur, J. C., and Ambinder, R. F. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet, 338: 969-973, 1991.
7. Weiss, L., Movahed, L., Warnke, R., and Sklar, J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N. Engl. J. Med., 320: 502-506, 1989.
8. Hamilton-Dutoit, S. J., Rea, D., Raphael, M., Sandvej, K., Delecluse, J., Gisselbrecht, C., Marelle, L., van Krieken, J., and Pallesen, G. Epstein-Barr virus latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Am. J. Pathol., 14: 1072-1085, 1993.
9. Hamilton-Dutoit, S., Audouin, R., Diebold, J., Lisse, I., Pedersen, C., Oksenhendler, E., Marelle, L., and Pallesen, G. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in AIDS-related lymphomas: correlation with tumor morphology and primary site. Blood, 82: 619-624, 1993.
10. Kieff, E. Epstein-Barr virus and its replication. In: B. Fields, D. Knipe, and P. Howley (eds.). Field's Virology, Ed. 3, pp. 2343-2396. Philadelphia: Lippincott-Raven Publishers, 1996.
11. Kawanishi, M. Epstein-Barr virus induces fragmentation of chromosomal DNA during lytic infection. J. Virol., 67: 7654-7658, 1993.
12. Chevallier-Greco, A., Manet, E., Chavrier, P., Mosnsier, C., Daillie, J., and Sergeant, A. Both Epstein-Barr virus (EBV) encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an early EBV promoter. EMBO J., 5: 3243-3249, 1986.
13. Rooney, C., Rowe, D., Ragot, T., and Farrell, P. The spliced BZLF1 gene of Epstein-Barr virus transactivates an early EBV promoter and induces the virus productive cycle. J. Virol., 63: 3109-3116, 1989.
14. Kenney, S., Kamine, J., Holley-Guthrie, E., Lin, J-C., Mar, E-C., and Pagano, J. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J. Virol., 63: 1729-1236, 1989.
15. Quinlivan, E., Holley-Guthrie, E., Norris, M., Gutsch, D., Qin, Z., Bachenheimer, S., and Kenney, S. The role of BZLF1 and BRLF1 response elements in activation of the EBV early promoter, BMRF1. Nucleic Acids Res., 21: 1999-2007, 1993.
16. Chang, Y., Dong, D., Hayward, G., and Hayward, S. D. The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J. Virol., 64: 3358-3369, 1990.
17. Hardwick, J. M., Lazarowits, S., and Hayward, S. D. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol., 62: 2274-2284, 1988.
18. Gruffat, H., Manet, E., Rigolet, A., and Sergeant, A. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence specific DNA binding protein. Nucleic Acids Res., 18: 6835-6843, 1990.
19. Countryman, J., and Miller, G. Activation of expression of latent Epstein-Barr virus after gene transfer with a small cloned fragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA, 82: 4085-4089, 1985.
20. Takada, K., Shimizu, N., Sakuma, S., and Ono, Y. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol., 57: 1016-1022, 1986.
21. Rooney, C., Taylor, N., Countryman, J., Jenson, H., Kolman, J., and Miller, G. Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc. Natl. Acad. Sci. USA, 85: 9801-9805, 1988.
22. Zalani, S., Holley-Guthrie, E., and Kenney, S. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. USA, 93: 9194-9199, 1996.
23. Ashton, W. T., Karkas, J. D., Field, A. K., and Tolman, R. L. Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG). Biochem. Biophys. Res. Commun., 108: 1716-1721, 1982.
24. Sullivan, V., Talarico, C., Stanat, S., Davis, M., Coen, D. M., and Biron, K. K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature (Lond.), 358: 162-164, 1992.
25. Freeman, S. M., Aboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. The "bystander" effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274-5283, 1993.
26. Tiberghien, P. Use of suicide genes in gene therapy. J. Leukocyte Biol., 56: 203-209, 1994.
27. Connors, T. A. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther., 2: 702-709, 1995.
28. Littler, E., and Arrand, J. Characterization of the Epstein-Barr virus-coded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems. J. Virol., 62: 3892-2895, 1988.
29. Cazaux, C., Tiraby, M., Loubiere, L., Haren, L., Klatzman, D., and Tiraby, G. Phosphorylation and cytotoxicily of therapeutic nucleoside analogues: a comparison of α and γ herpesvirus thymidine kinase suicide genes. Cancer Gene Ther., 5: 83-91, 1098.
30. Lin, J-C., Nelson, D., Lambe, C., and Cho, E. Metabolic activation of 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine in human lymphoblastoid cell lines infected with Epstein-Barr virus. J. Virol., 60: 569-573, 1986.
31. Lin, J-C., Smith, C., and Pagano, J. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J. Virol., 50: 50-55, 1984.
32. Rogers, R., Ge, J-Q., Holley-Guthrie, E., Hoganson, D., Comstock, K., Olsen, J., and Kenney, S. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum. Gene Ther., 7: 2235-2245, 1996.
33. Takimoto, T., Kamide, M., and Umeda, R. Establishment of Epstein-Barr virus (EBV) associated nuclear antigen (EBNA)-positive nasopharyngeal carcinoma hybrid cell line (NPC-KT). Arch. Otorhinolaryngol., 239: 87-92, 1984.
34. Hardy, S., Kitamura, M., Harns-Stansil, T., Dai, Y., and Phipps, L. Construction of adenovirus vectors through cre-lox recombination. J. Virol., 71: 1842-1849, 1997.
35. Baer, R., Bankier, A., Biggen, M., Deininger, P. L., Farrell, P. J., Gibson, T. J., Hatfull, G., Hudson, G. S., Satchwell, S. C., Seguin, C., Tuffnell, P. S., and Barrell, B. G. DNA sequence and expression of the B95-8 Epstein-Barr virus. Nature (Lond.), 310: 207-211, 1984.
36. Zhang, Q., Hong, Y., Dorsky, D., Holley-Guthrie, E., Zalani, S., Aly Elshiekh, N., Kiehl, A., Le, T., and Kenney, S. Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: effects on EBV transcription and lytic replication. J. Virol., 70: 5131-5142, 1996.
37. Raab-Traub, N., and Flynn, K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell, 47: 883-889, 1986.
38. Fyfe, J. A., McKee, S. A., and Keller, P. M. Altered thymidine-thymidylate kinases from strains of herpes simplex virus with modified drug sensitivities to acyclovir and (E)-5-(2-bromo-vinyl)-2′-deoxyuridine. Mol. Pharmacol., 24: 316-323, 1983.
39. 1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J., 15: 2748-2759, 1996.
40. Guitierrez, M. I., Judde, J. G., Magrath, I., and Bhatia, K. G. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res., 56: 969-972, 1996.
41. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. A novel assay for apoptosis flow cytometric detection of phophatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods, 184: 39-51, 1995.
42. Ragoczy, T., Heston, L., and Miller, G. The Epstein-Barr virus Rta protein disrupts latency in B lymphocytes. J. Virol., 72: 7978-7984, 1998.
43. Reisman, D., and Sugden, B. Transactivation of an EBV transcriptional enhancer by the Epstein-Barr virus nuclear antigen-1. Mol. Cell. Biol., 6: 3838-3846, 1986.
44. Franken, M., Estabrooks, A., Cavacni, L., Sherburne, B., Wang, F., and Scadden, D. Epstein-Barr virus-driven gene therapy for EBV-related lymphomas. Nat. Med., 2: 1379-1382, 1996.
45. Lin, J. C., Zhang, Z. X., Smith M. C., Biron, K., and Pagano, J. Anti-human immunodeficiency virus agent 3′ azido-3′-deoxythymidine inhibits replication of Epstein-Barr virus. Antimicrob. Agents Chemother., 32: 265-267, 1988.
46. Huang, S., Stupack, D., Mathias, P., Wang, Y., and Nemerow, G. Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. Proc. Natl. Acad. Sci. USA, 94: 8156-8161, 1997.
47. Huang, M. R . Olsson, M., Kallin, A., Pettersson, U., and Toetterman, T. H. Efficient adenovirus-mediated gene transduction of normal and leukemic hematopoietic cells. Gene Ther., 4: 1093-1099, 1997.
48. Wickham, T., Lee, G., Titu, J., Sconocchia, G., Bakacs, T., Kovesdi, I., and Segal, D. Targeted adenovirus-mediated gene delivery to T cells via CD3. J. Virol., 71: 7663-7669, 1997.
49. Ambinder, R., Robertson, K., Moore, S., and Yang, J. Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin. Cancer Biol., 7: 217-227, 1996.
50. Judde, J-G., Spangler, G., Magrath, I., and Bhatia, K. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum. Gene Ther., 7: 647-653, 1996.
51. Kenney, S., Ge, J-Q., Westphal, E. M., and Olsen, J. Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors. Hum. Gene Ther, 9: 1131-1141, 1998.
52. Mucke, S., Polack, A., Pawlita, M., Zehnpfennig, D., Massoudi, N., Bohlen, H., Doerfler, W., Bornkamm, G., Diehl, V., and Wolf, J. Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells. Gene Ther., 4: 82-92, 1997.